Senti Biosciences Holdings (SNTI) Capital Expenditures (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Capital Expenditures of $26000.0 for Q2 2025, down 84.71% quarter-over-quarter from $170000.0 in Q1 2025.
Senti Biosciences Holdings (SNTI) Capital Expenditures (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Capital Expenditures history runs 5 years deep, the most recent figure standing at $26000.0 for Q2 2025.
- In Q2 2025, Capital Expenditures changed N/A year-over-year to $26000.0; the TTM figure through Dec 2025 stood at $196000.0 (up 653.85% YoY), while the FY2025 annual figure was $196000.0, up 653.85% from the prior year.
- Capital Expenditures for Q2 2025 stood at $26000.0, down from $170000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $34.0 million in Q4 2022, with the low at -$11.3 million in Q3 2022.
- The 5-year median for Capital Expenditures is $650500.0 (2021), against an average of $3.3 million.
- Peak annual rise in Capital Expenditures reached 1080.63% in 2022, while the deepest fall reached 1097.35% in 2022.
- Senti Biosciences Holdings' Capital Expenditures stood at $2.9 million in 2021, then soared by 1080.63% to $34.0 million in 2022, then tumbled by 99.96% to $12000.0 in 2023, then fell by 8.33% to $11000.0 in 2024, then surged by 136.36% to $26000.0 in 2025.
- Business Quant data shows SNTI's Capital Expenditures at $26000.0 in Q2 2025, $170000.0 in Q1 2025, and $11000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | -10.17 Mn |
| Sep 30, 2023 | -10.17 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 6.51 Mn |
| Mar 31, 2023 | 6.51 Mn |
| Dec 31, 2022 | 34.01 Mn |
| Dec 31, 2022 | 34.01 Mn |
| Sep 30, 2022 | -11.28 Mn |
| Sep 30, 2022 | -11.28 Mn |